CorMedix announced that the U.S. Food and Drug Administration has approved DefenCath catheter lock solution to reduce the incidence of catheter-related bloodstream infections for the limited population of adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. “DefenCath is the first and only FDA-approved antimicrobial CLS in the U.S. and was shown to reduce the risk of CRBSIs by up to 71% in a Phase 3 clinical study,” the company stated. Joseph Todisco, CEO of CorMedix commented, “The approval of DefenCath marks a major advancement in reducing life-threatening infections for patients receiving hemodialysis via central venous catheters and an important milestone for CorMedix. As the first FDA-approved antimicrobial catheter lock solution designed to prevent CRBSIs, DefenCath offers healthcare providers an option to reduce the risk of infections in a patient population already vulnerable due to underlying kidney failure. We thank all the patients, caregivers, clinical investigators, and our employees who have played an integral role in the development and regulatory approval of DefenCath. Our commercial team along with our broader organization is preparing for commercial launch, and we look forward to working with healthcare providers and facilities to give hemodialysis patients access to DefenCath in early 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRMD:
- CorMedix Inc. Announces FDA Approval of DefenCath® to Reduce the Incidence of Catheter-Related Bloodstream Infections in Adult Hemodialysis Patients
- Biotech Alert: Searches spiking for these stocks today
- CorMedix price target raised to $10 from $6 at RBC Capital
- CorMedix reports Q3 EPS (17c), consensus (21c)
- CorMedix Inc. Reports Third Quarter and Nine Month 2023 Financial Results and Provides Business Update